MedTrace Logo

Safety and Immunogenicity of Oxford AstraZeneca Vaccine Against COVID-19 Infection

NCT04756271 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 246

Last updated 2022-02-09

No results posted yet for this study

Summary

After SARS-COV-2 inactivated vaccine authorization for use in different countries including Egypt, investigating its immunogenicity, safety, and efficacy in preventing COVID-19 infection is highly needed. In Egypt, immunization of HCWs in isolation hospitals by SARS-COV-2 inactivated vaccine is now a national priority. Moreover, data and reports regarding the application of vaccine are still limited and deficient.

Conditions

  • Vaccine Adverse Reaction
  • Seroconversion

Interventions

BIOLOGICAL

SARS-Cov-2 neutralizing antibody titer

Quantitation of SARS-Cov-2 antibody titer at baseline after each dose of the vaccine

Sponsors & Collaborators

  • Zagazig University

    lead OTHER_GOV

Principal Investigators

  • Noha M Hammad, MD · Faculty of Medicine, Zagazig University , Zagazig, Egypt

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-11
Primary Completion
2021-12-20
Completion
2021-12-22

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04756271 on ClinicalTrials.gov